Go Pro
LON:DXRX

Diaceutics Interim Earnings Report

Diaceutics logo
GBX 135 +0.50 (+0.37%)
As of 04:18 AM Eastern

Diaceutics EPS Results

Actual EPS
-GBX 2.84
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Diaceutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Diaceutics Announcement Details

Quarter
Interim
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Diaceutics Earnings Headlines

A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.tc pixel
Diaceutics PLC Expands Employee Share Incentive Plan
See More Diaceutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Diaceutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Diaceutics and other key companies, straight to your email.

About Diaceutics

At Diaceutics (LON:DXRX) we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.

View Diaceutics Profile